Senzime AB (OSTO:SEZI) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:SEZI Senzime AB OSTO:SEZI
71 GF Score
Price kr3.60
GF Value kr9.06
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Senzime AB FFO?

FFO (Funds from operations) only applies to REITs.

OSTO:SEZI
71GF Score
Senzime AB OSTO:SEZI
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Senzime AB (OSTO:SEZI) Overvalued in 2026?

Based on GuruFocus' analysis, Senzime AB stock appears to be undervalued. The current stock price of kr3.60 is trading 60.3% below its estimated GF Value™ of kr9.06. GuruFocus considers Senzime AB to be Possible Value Trap.

Key valuation signals for OSTO:SEZI:

  • FFO:
  • GF Value™: kr9.06 vs. price of kr3.60 (60.3% below fair value)
  • GF Score™: 71/100 with 3 warning signs

No single metric tells the full story. See the OSTO:SEZI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Senzime AB Business Description

Other Exchanges SNZZF:USA6YC:Germany
Address Verkstadsgatan 8, hus 1, Uppsala, SWE, 753 23
Senzime AB is a medical device company developing precision-based patient monitoring solutions for patients undergoing anesthesia. The company develops and markets precision-based monitoring systems for monitoring neuromuscular function and respiration during and after surgery, as well as for intensive care. Its product portfolio includes Next-generation TetraGraph, TetraGraph connectivity, TetraGraph for pediatric, Classic TetraGraph, and ExSpiron. The TetraGraph system is used in thousands of operating rooms internationally in university hospitals, public, private, military, and veterans hospitals. Senzime has direct sales resources in the USA and Germany and collaborates with distributors and licensees in its other main markets.
71GF Score

Get the complete analysis for OSTO:SEZI

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr3.60
Price
kr9.06
GF Value